Lisette Olie
University of Groningen
7 Papers
11 Citations
Lisette Olie is an academic researcher from University of Groningen. The author has contributed to research in topics: Abatacept & Medicine. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
Abatacept treatment for patients with early active primary Sjogren's syndrome : a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)
Jolien F van Nimwegen,Esther Mossel,Greetje S. van Zuiden,Robin F. Wijnsma,Konstantina Delli,Alja J Stel,Bert van der Vegt,Erlin A. Haacke,Lisette Olie,Leonoor I. Los,Gwenny M Verstappen,Sarah Pringle,Fred K L Spijkervet,Frans G. M. Kroese,Arjan Vissink,Suzanne Arends,Hendrika Bootsma +16 more
- 01 Mar 2020
TL;DR: This trial cannot recommend abatacept treatment as standard of care to reduce systemic disease activity in patients with primary Sjogren's syndrome, and further studies should evaluate whether patients with specific clinical manifestations and biological characteristics might benefit from abatACEpt treatment.
Long-term abatacept treatment for 48 weeks in patients with primary Sjögren's syndrome: The open-label extension phase of the ASAP-III trial.
Liseth de Wolff,Jolien F van Nimwegen,Esther Mossel,Greetje S. van Zuiden,Alja J Stel,K I Majoor,Lisette Olie,Leonoor I. Los,Arjan Vissink,Frederik Spijkervet,Gwenny M Verstappen,Frans G. M. Kroese,Suzanne Arends,Hendrika Bootsma +13 more
TL;DR: The ASAP-III trial as mentioned in this paper investigated treatment efficacy of long-term abatacept treatment in pSS patients, which consisted of two phases: the randomised, double-blind, placebo-controlled phase (1:1 randomisation) from baseline to week 24, and the open-label extension phase from week 24 to 48, in which all patients received abacept.
25
Abatacept treatment of patients with early active primary sjogren's syndrome - a randomized, double-blind placebo-controlled phase iii-study (asap-iii)
Jolien F van Nimwegen,Greetje S. van Zuiden,Suzanne Arends,Esther Mossel,Robin F. Wijnsma,Alja J Stel,Konstantina Delli,Bert van der Vegt,Erlin A. Haacke,Lisette Olie,Leonie Los,Janita Bulthuis-Kuiper,Gwenny M Verstappen,Sarah Pringle,Fred K L Spijkervet,Frans G. M. Kroese,Arjan Vissink,Hendrika Bootsma +17 more
TL;DR: The ASAP-III trial was designed to assess the clinical efficacy and safety of SC abatacept in pSS patients with short disease duration and active disease, and the occurrence of (serious) adverse events and treatment discontinuation.
10
Patient Acceptable Symptom State (PASS) in patients with primary Sjögren's syndrome in daily clinical practice.
Liseth de Wolff,Arjan Vissink,Jolien F van Nimwegen,Greetje S. van Zuiden,Esther Mossel,Lisette Olie,Alja J Stel,Konstantina Delli,Gwenny M Verstappen,Frans G. M. Kroese,Hendrika Bootsma,Suzanne Arends +11 more
TL;DR: In this paper , the authors explore Patient Acceptable Symptom State (PASS) in a standard of care cohort of patients with primary Sjögren's syndrome (pSS) and compare patient characteristics including EULAR Patient Reported Index (ESSPRI) between PASS and non-pass groups.
•Journal Article
Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjogren's Syndrome - Open-label Extension Phase of a Randomized Controlled Phase III Trial
Jolien F van Nimwegen,Esther Mossel,Robin F. Wijnsma,Greetje S. van Zuiden,Konstantina Delli,Alja J Stel,Bert van der Vegt,Erlin A. Haacke,Lisette Olie,Leonie Los,Gwenny M Verstappen,Sarah Pringle,Fred K L Spijkervet,Frans G. M. Kroese,Arjan Vissink,Suzanne Arends,Hendrika Bootsma +16 more
1